MiNK Therapeutics clarified that it is engaged in discussions with multiple parties regarding potential combination trials for its iNKT cell therapy agenT-797 and potential strategic minority investments, but has not entered into any binding arrangements. This disclosure addresses investor inquiries about third-party postings and highlights growing interest in the company's platform.
Key takeaways
MiNK Therapeutics is in discussions with multiple parties regarding potential combination trials involving agenT-797.
The company is also discussing potential strategic minority investments with multiple parties.
No binding arrangements have been publicly disclosed regarding these combination trials or strategic investments.
The company believes these discussions reflect growing interest in its platform, including potential applications in critical illness.
The disclosure was made in response to recent investor inquiries about third-party postings.